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Abstract:  
Non-alcoholic fatty liver disease constitutes a newly recognized integral component of the 
metabolic syndrome. In its uncomplicated form (simple steatosis) it is asymptomatic. However a 
subset progresses to more severe manifestations including Non Alcoholic Steatoric Hepatitis, 
fibrosis, cirrhosis and liver failure. Indeed it is now recognized as the most common cause of 
cryptogenic cirrhosis. Biochemical markers of significance like Aminotransferases and Lipid 
profile were analysed in this study  
Material and Methods: 50 Diabetic and 50 Nondiabetics subjects between 20 to 70 years were 
taken as cases and controls. Patients with Liver diseases, abnormal hemoglobins, hemolytic 
disorders, alcoholics and smokers were excluded from the study. Aminotransferases were 
estimated using end point kinetic method and Lipid profile were estimated using enzymatic 
methods. 
Results:Study showed an significant increase in Aminotransferase levels . In both male and 
female cases showed elevated triglycerides and a low High density lipoprotein. 
Conclusion and recommendationsThese observations indicate Aminotransferases and other 
markers of liver injury may be usefulsurrogate measures of Non alcoholic fatty liver disease and 
related conditions in Diabetes mellitus. Study found that both male as well as female patients had 
low High density lipoprotein and high Triglycerides which makes the liver more prone for Fatty 
changes and leads to progression towards the disease .Whether determination of aminotransferase 
concentrations and lipid profile is a useful tool as markers of liver injury in patients with Diabetes 
awaits replication of our results in other settings and in different populations with larger sample 
sizes. 
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INTRODUCTION 
Diabetes mellitus is a metabolic disease 
characterized by hyperglycemia resulting from 
defect in insulin secretion, insulin action or both.  
Asian Indians are at high risk of type 2 
diabetes and cardiovascular
 
disease and have an 
insulin-resistant phenotype, characterized
 
by low 
muscle mass, upper-body adiposity, and high 
percentage
 
of body fat 
(1,2,3).
 While insulin 
resistance runs in families
 
and may have a genetic 
basis
(4,5)
.  
The world  wide  prevalence of  diabetes  
mellitus  has  risen  dramatically  over  past  two  
decades . About 10% of the total population and 
about 1/5
th
 of people above 50 years suffer from 
this disease. Diabetes currently affects 246 million 
people worldwide and is expected to affect 380 
million by 2025. In 2007, the five countries with 
the largest number of people with diabetes are 
India (40.9 million), China (39.8 million), the 
United States (19.2 million), Russia (9.6 million) 
and Germany (7.4 million). Each year a further 7 
million people develop diabetes. These statistics 
describes diabetes as “one of the main threat to 
human health in 21
st
 century”.(6.7)                    
             Recently a novel hepatic sequealea of 
obesity has been described: NAFLD
(8,9)
 which is 
defined as “significant lipid deposition” in the 
hepatocytes of the liver parenchyma in a patient 
without a history of excessive alcohol ingestion
(8).
 
It constitutes a newly recognized integral 
component of the metabolic syndrome 
[10, 11].
 
NAFLD in its uncomplicated form (simple 
steatosis) are asymptomatic. However a subset 
progresses to more severe manifestations of the 
NAFLD disease spectrum including (NASH), 
fibrosis, cirrhosis and liver failure.
(8,9)
 Indeed 
NAFLD is now recognized as the most common 
cause of cryptogenic cirrhosis
(12)
. The 
pathophysiological mechanism underlying NAFLD 
is currently unknown, although the close link with 
overweight and obesity has suggested a role for 
Insulin Resistance (IR).This hypothesis is 
supported by observational studies that have 
documented elevated prevalence rates of metabolic 
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syndrome, IR, and /or type 2 DM among patients 
with NAFLD 
(13,14).
 As well as recent clinical trial 
data showing improvements in NAFLD and 
reduction in liver fat content after treatment with 
insulin sensitizing agents, including 
thiazolidinediones and Metformin
(15-18)
. , NAFLD 
is associated with insulin resistance irrespective
 
of 
BMI, fat distribution, and glucose tolerance 
(19-21)
. 
On
 
these grounds, it has been suggested that 
hyperinsulinemia and
 
insulin resistance may play a 
role in the pathogenesis of  NAFLD
(19)
 and that 
NAFLD is a feature of the metabolic syndrome 
(21)
.
 
 
Further, elevated aminotransferases 
(alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST)) are surrogate markers of 
liver fat content 
[10,11]
 and analysis of the data from 
the Third National Health and Nutrition 
Examination Survey revealed a strong association 
of unexplained aminotransferase elevations with 
metabolic syndrome features 
[22].
     In a prospective 
study in Pima Indians, serum ALT concentrations
 
were related to both hepatic insulin resistance and 
later decline
 
in hepatic insulin sensitivity 
.
 In 
contrast, aspartate
 
aminotransferase (AST) and -
glutamyltransferase (GGT) concentrations
 
were 
unrelated to changes in hepatic insulin action 
(23)
Based
 
on previous findings ,Vozarova et al. 
(24)
 
suggested that
 
a raised ALT reflects fatty changes 
in the liver and that this
 
abnormality antedates the 
development of type 2 diabetes.  
All Indians are at high risk of Type2 
diabetes and cardiovascular disease and have 
insulin resistance phenotype, characterized by low 
muscle mass, upper body adipocity and high 
percentage of body fat
(1-3)
 while insulin resistance 
runs in families and have genetic basis
(4,5)
. It is 
often lifestyle factors
 
that trigger the 
cardiometabolic disease processes 
(25).
 With
 
India 
undergoing rapid industrialization and 
urbanization, the
 
consequent changes in the form of 
sedentary lifestyle are rampant
(26,27).
 
Since a limited number of studies have 
reported association between serum transaminase 
and diabetes type II  the study was done to  
Estimate Serum Transaminase as a marker of 
NAFLD in type II diabetic patients.  
AIMS AND OBJECTIVES 
Aim: TO study the prevalence of NAFLD in D.M. 
in a rural area. 
Objectives: 
1.To estimate serum lipid profile in diabetes.  
2. To estimate serum transaminase as a marker of 
NAFLD in diabetics and  controls. 
MATERIALS AND METHODS 
I) Cases and controls 
50 clinically diagnosed diabetis patients were 
taken as cases.                                  
         50 Nondiabetic individuals are taken as 
controls. 
 II) Inclusion and exclusion criteria:  
INCLUSION: 
Type 2 diabetes patients are included. Age Group 
between 35- 70 yrs  
           EXCLUSION: 
Patients with: Nephrotic syndrome,Abnormal 
hemoglobin,Gestational syndrome,Liver disease 
,Heamolytic disorders,Multiple 
myeloma,Heamoglobinopathies,Alcoholics and 
smokers were excluded from the study. 
PARAMETERS 
PRINCIPLES AND METHODS: 
I.SERUM TRANSAMINASE 
1) SGPT (ALT)- Alanine Transaminase. 
Method: Modified IFCC –UV kinetic method 
Principle: SGPT catalyses the transfer of aminogroups from L-Alanine to  2-Oxoglutarate.The rate of reaction 
is monitored using a coupling enzyme LDH, Where by pyruvate is converted to lactate in presence of NADH. 
Oxidation of NADH is measured by monitoring the decrease in absorbance at 340nm. 
L-Alanine +2-Oxo-glutarate           SGPT  Pyruvate+L-Glutamate 
Pyruvate+NADH+H
+                                
LDH
  
             L-Lactate+NAD
+
 
NORMAL RANGE:   MALES: up to 40U/L 
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 FEMALES: up to 30U/L 
Specimen: Un hemolysed serum /EDTA plasma 
Reference values: Males: 15-37IU/L 
                          FEMALES: 15-30IU/L. 
2.SGOT (AST) – Aspartate Transaminase. 
Method: Modified IFCC-UV Kinetic method. 
Principle:   
L-Aspartate+ -Ketoglutarate                   SGOT      Oxalo actate+L-glutamate 
Oxaloacetate+NADH+H
+                                     
MDH   
          
Malate +NAD
+
 
NORMAL RANGE:  MALES:  up to 37IU/L at 37 C 
   FEMALES: up to 30IU/L at 37 C 
SPECIMEN:  Unhaemolysed serum /EDTA plasma. 
 Reference values: Males:15-37 IU/L 
                                 FEMALES:15-30 IU/L. 
3.LIPID PROFILE 
1) SERUM TOTAL CHOLESTROL: 
METHOD: CHOD-POD method 
Principle: 
Cholesterol ester +H2O                CHE                  Chol+FFA 
Cholesterol +02   CHO        Cholest-4-enezone+H202 
2H2O2+phenol+4-amino anti pyrine                     POD         Redquinoneimine complex+H2o         
 
Cholesterol is determined after enzymatic hydrolysis and oxidation. Cholesterol esters are hydrolyzed by the 
enzyme cholesterol esterase to give free cholesterol and fatty acid molecules. This free cholesterol gets 
oxidized in the presence of cholesterol oxidase to liberate cholest-4-ene-3one and peroxide. The indicator 
quinoneimine is formed from H2O2 and 4-amino antipyrine in the presence of phenol and peroxidase .The 
intensity of this colored complex is measured at 505nm and is directly proportional to the cholesterol 
concentration. present in the sample. On addition of precipitating reagent to the sample followed by 
centrifugation, HDL fraction remains in the supernatant while the other lipo proteins precipitate out. 
NORMAL RANGE: Total cholesterol                   130-250mg% 
 
2.HDL cholesterol  
                MALES                                30-70mg/dl 
               FEMALES                            35-90mg/dl 
SPECIMEN:  
 Serum heparinised /EDTA sample.Reading at 510nm. 
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HDL: 
              Sr 200µl in to one test tube 
                             ↓  
             Ppt reagent 300µl in to same test tube 
                             ↓ 
                      5 min RT 
             Centrifuge at 3000rpm for 5 min               Supernatant 100µL 
                     1ml cholesterol reagent                        
                             ↓                        
                      5min water bath 
                              ↓ 
                       Reading.    
 
  
High Normal  :  250 
Linearity: Linearity of the kit up to 750mg/d 
3.TRIGLYCERIDES 
METHOD: GPO-POD method 
PRINCIPLE: 
TG+H20 Lipases Glycerol + FA 
Glycerol + ATP GK       Gly- 3-P+ADP. 
G-3-P+O2  GPO      H2O2 + DHAP. 
H2O2+4Aminoantipyrine +ESPAS POD Quinoneimine complex +H2O+Hcl 
TGL are determined after enzymatic hydrolysis with lipase. Serum TGL is hydrolyzed to glycerol and 
FFA by lipases. In the presence of ATP And glycerol kinase, glycerol is converted to glycerol 3 P which is then 
oxidized by GPO to yield H2O2peroxidase catalyses the conversation of H2O2, 4-amini antipyrine and ESPAS to 
a colored Quinoneimine complex measurable at 546nm.          
Normal Range; Up to 150 mg/dl. 
 All the parameters quality control was done with the help of  QC1and QC2 were provided by Bio –Rad 
used for quality checks. 
RESULTS 
TABLE: 1 
Transaminase activity in Diabetic and in controls. 
  
Parameters 
Controls( n=50) Diabetics (n=50) P- Value 
Males n=26 Females n=24 Males n=26 
Females 
n=24 
Males Females 
SGOT  
(AST) U/L Mean 
±SD 
32.96±11.98 23.79±7.38 46.70±5.47 30.25±11.08 0.05 0.02 
SGPT 
(ALT) U/L     
Mean ±SD 
28.19±10.36 26.72±9.17 47.51±23.05 31.91±4.45 0.06 0.02 
 
 The table I shows that Serum transaminases , SGOT(AST) and SGPT(ALT) recorded a significacnt 
increase in their levels when compared with controls. Transaminases in males showed a higher activity in 
comparison to activity in females. 
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TABLE: II   
Analysis of Chlesterol and triglyceride levels in controls and in Diabetic patients. 
 
Parameters 
Controls( n=50) Diabetics (n=50) P- Value 
Males n=26 Females n=24 Males n=26 
Females 
n=24 
Males Females 
Cholesterol 
(mg/dl)                
Mean ±SD 
145.3±13.79 148.3±34.3 161.3±44.98 158.1±37.08 < 0.08 <0.07 
HDL (mg/dl) 
Mean ±SD 
50.34±18.54 41.03±17.7 39.25±7.45 39.05±18.15 < 0.07 < 0.09 
TGL (mg/dl) 
Mean ±SD 
137±10.08 111.5±1.29 183.9±80.03 177.7±80.39 < 0.01 < 0.007 
 
 The table II shows that cholesterol and 
Triglycerides were increased in patients with 
minimal  gender variations in patients in 
comparison to controls. Whereas HDL showed a 
decreasing trend in both males and female patients 
in comparison to controls.   
 
DISCUSSION 
Public Health implications of the emerging 
pandemic of NAFLD are dire in light of the 
growing list of more severe manifestations such as 
NASH,Fibrosis,Cirrhosis and Liver Failure. 
In This study,which include 50 patients and 50 
controls,AST and ALT were studied as markers of 
liver injury in type 2 DM. 
 Both AST and ALT levels were found to 
increase ,when compared with controls which is in 
accordance with Samela  et al study and jick et al 
studies
(28,29)
.Similar results were seen in studies 
done by Golay A etal, Mulhall BP et al and Clark 
JM et al.
(30-32)
These observations indicate
 
that AST, 
ALT, and other markers of liver injury may be 
useful
 
surrogate measures of NAFLD and related 
conditions for large
 
studies in DM. 
 IN this study ,AST and ALT  levels were  
increased. Both ALT and AST were independently
 
associated with diabetes which was in accordance 
with by work done by Leed.h et al, in a cohort of 
male Korean workers
 (33)
.  
 In diabetic males and females cases there 
is low HDL cholesterol followed by elevation in 
TGL as shown in table II. Observation of  Low 
HDL cholesterol levels seen were in accordance 
with studies done by Ramchandran A et al in 
Indian population and with Dixon et al in Asian -
Indian population.
(34,35).
Study found that both male 
as well as female patients had low High density 
lipoprotein  and high Triglycerides  which makes 
the liver more prone for Fatty changes and leads to 
progression towards the disease . 
 CONCLUSION 
Our findings suggest that, within currently 
recommended reference ranges, there is elevation 
of serum transaminases in Diabetes. Moreover, 
such aminotransferase elevations were closely 
associated with Liver disorders in Diabetics. 
Whether determination of aminotransferase 
concentrations is a useful tool  as markers of liver 
injuryin patients with Diabetes awaits replication of 
our results in other settings and in different 
populations with larger sample sizes.                  
 
PROFORMA 
Name:                                                                    Age: 
Sex:                                                                        IP/OP no. : 
Marital status:                                              Occupation: 
Address: 
Height: 
Weight: 
Waist circumference: 
HIP circumference: 
W/h ratio: 
Parameters 
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